Rilonacept + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Pericarditis
Conditions
Recurrent Pericarditis
Trial Timeline
Jan 7, 2019 → Jun 30, 2022
NCT ID
NCT03737110About Rilonacept + Placebo
Rilonacept + Placebo is a phase 3 stage product being developed by Kiniksa Pharmaceuticals for Recurrent Pericarditis. The current trial status is completed. This product is registered under clinical trial identifier NCT03737110. Target conditions include Recurrent Pericarditis.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Pericarditis were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03737110 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Pericarditis